Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q3 2023 ▲▼ | Q4 2023 ▲▼ | Change ▲▼ | Q3 2023 ▲▼ | Q4 2023 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Pharvaris N.V. COM | 3,743,450 | 4,038,842 | +295,392 | $78.13M | $113.29M | 57.25% | +$35.16M |
| Kura Oncology, Inc.(KURA) | 1,849,947 | 1,849,947 | 0 | $16.87M | $26.60M | 13.44% | +$9.73M |
| Kinnate Biopharma Inc. | 9,671,643 | 9,671,643 | 0 | $13.54M | $22.92M | 11.58% | +$9.38M |
| Syndax Pharmaceuticals, Inc.(SNDX) | 875,000 | 875,000 | 0 | $12.71M | $18.91M | 9.56% | +$6.20M |
| Lyell Immunopharma, Inc.(LYEL) | 8,784,813 | 8,325,000 | -459,813 | $12.91M | $16.15M | 8.16% | +$3.24M |
| Aclaris Therapeutics, Inc.COM(ACRS) | 2,808,034 | 0 | -2,808,034 | $19.24M | $0 | — | -$19.24M |
| Cymabay Therapeutics, Inc.COM | 1,787,094 | 0 | -1,787,094 | $26.65M | $0 | — | -$26.65M |